Outcomes in the 12 Months Following First Diagnosis of Clostridium difficile Infection Episode, 2016–2021
| Outcome . | CDI (n = 7807a) . |
|---|---|
| Healthcare utilization | |
| Virtual CDI-associated visits, mean (range), median | 0.3 (0–13), 0 |
| Outpatient CDI-associated visits, mean (range), median | 0.6 (0–134), 0 |
| Emergency CDI-associated department visits, mean (range), median | 0.2 (0–13), 0 |
| Any CDI-associated hospitalization, No. (%) | 526 (6.7) |
| C difficile laboratory testing | |
| Any C difficile testing in 365 d after index date, No. (%) | 2566 (32.9) |
| Timing of C difficile testing among those tested, No. (%) | |
| 1–14 d after index date | 151 (5.9) |
| 15–56 d after index date | 1376 (53.6) |
| 57–180 d after index date | 709 (27.6) |
| 181–365 d after index date | 330 (12.9) |
| Treatment for CDI | |
| Outpatient treatment dispensing, No. (%) | |
| Any treatmentb | 5653 (72.4) |
| Vancomycin | 4820 (61.7) |
| Metronidazole | 1107 (14.8) |
| Fidaxomicin | 382 (4.9) |
| Timing of first treatment, among those treated, No. (%) | |
| Same day of index date | 713 (12.6) |
| 1–56 d after index date | 4784 (84.6) |
| 57–180 d after index date | 111 (2.0) |
| 181–365 d after index date | 45 (0.8) |
| No. of treatment dispensings, mean (SD) | 2.0 (1.8) |
| Outcome . | CDI (n = 7807a) . |
|---|---|
| Healthcare utilization | |
| Virtual CDI-associated visits, mean (range), median | 0.3 (0–13), 0 |
| Outpatient CDI-associated visits, mean (range), median | 0.6 (0–134), 0 |
| Emergency CDI-associated department visits, mean (range), median | 0.2 (0–13), 0 |
| Any CDI-associated hospitalization, No. (%) | 526 (6.7) |
| C difficile laboratory testing | |
| Any C difficile testing in 365 d after index date, No. (%) | 2566 (32.9) |
| Timing of C difficile testing among those tested, No. (%) | |
| 1–14 d after index date | 151 (5.9) |
| 15–56 d after index date | 1376 (53.6) |
| 57–180 d after index date | 709 (27.6) |
| 181–365 d after index date | 330 (12.9) |
| Treatment for CDI | |
| Outpatient treatment dispensing, No. (%) | |
| Any treatmentb | 5653 (72.4) |
| Vancomycin | 4820 (61.7) |
| Metronidazole | 1107 (14.8) |
| Fidaxomicin | 382 (4.9) |
| Timing of first treatment, among those treated, No. (%) | |
| Same day of index date | 713 (12.6) |
| 1–56 d after index date | 4784 (84.6) |
| 57–180 d after index date | 111 (2.0) |
| 181–365 d after index date | 45 (0.8) |
| No. of treatment dispensings, mean (SD) | 2.0 (1.8) |
Abbreviations: CDI, Clostridioides difficile infection; SD, standard deviation.
aIndividuals required at least 1 year of membership after C difficile index date.
bIncludes metronidazole, oral vancomycin, fidaxomicin.
Outcomes in the 12 Months Following First Diagnosis of Clostridium difficile Infection Episode, 2016–2021
| Outcome . | CDI (n = 7807a) . |
|---|---|
| Healthcare utilization | |
| Virtual CDI-associated visits, mean (range), median | 0.3 (0–13), 0 |
| Outpatient CDI-associated visits, mean (range), median | 0.6 (0–134), 0 |
| Emergency CDI-associated department visits, mean (range), median | 0.2 (0–13), 0 |
| Any CDI-associated hospitalization, No. (%) | 526 (6.7) |
| C difficile laboratory testing | |
| Any C difficile testing in 365 d after index date, No. (%) | 2566 (32.9) |
| Timing of C difficile testing among those tested, No. (%) | |
| 1–14 d after index date | 151 (5.9) |
| 15–56 d after index date | 1376 (53.6) |
| 57–180 d after index date | 709 (27.6) |
| 181–365 d after index date | 330 (12.9) |
| Treatment for CDI | |
| Outpatient treatment dispensing, No. (%) | |
| Any treatmentb | 5653 (72.4) |
| Vancomycin | 4820 (61.7) |
| Metronidazole | 1107 (14.8) |
| Fidaxomicin | 382 (4.9) |
| Timing of first treatment, among those treated, No. (%) | |
| Same day of index date | 713 (12.6) |
| 1–56 d after index date | 4784 (84.6) |
| 57–180 d after index date | 111 (2.0) |
| 181–365 d after index date | 45 (0.8) |
| No. of treatment dispensings, mean (SD) | 2.0 (1.8) |
| Outcome . | CDI (n = 7807a) . |
|---|---|
| Healthcare utilization | |
| Virtual CDI-associated visits, mean (range), median | 0.3 (0–13), 0 |
| Outpatient CDI-associated visits, mean (range), median | 0.6 (0–134), 0 |
| Emergency CDI-associated department visits, mean (range), median | 0.2 (0–13), 0 |
| Any CDI-associated hospitalization, No. (%) | 526 (6.7) |
| C difficile laboratory testing | |
| Any C difficile testing in 365 d after index date, No. (%) | 2566 (32.9) |
| Timing of C difficile testing among those tested, No. (%) | |
| 1–14 d after index date | 151 (5.9) |
| 15–56 d after index date | 1376 (53.6) |
| 57–180 d after index date | 709 (27.6) |
| 181–365 d after index date | 330 (12.9) |
| Treatment for CDI | |
| Outpatient treatment dispensing, No. (%) | |
| Any treatmentb | 5653 (72.4) |
| Vancomycin | 4820 (61.7) |
| Metronidazole | 1107 (14.8) |
| Fidaxomicin | 382 (4.9) |
| Timing of first treatment, among those treated, No. (%) | |
| Same day of index date | 713 (12.6) |
| 1–56 d after index date | 4784 (84.6) |
| 57–180 d after index date | 111 (2.0) |
| 181–365 d after index date | 45 (0.8) |
| No. of treatment dispensings, mean (SD) | 2.0 (1.8) |
Abbreviations: CDI, Clostridioides difficile infection; SD, standard deviation.
aIndividuals required at least 1 year of membership after C difficile index date.
bIncludes metronidazole, oral vancomycin, fidaxomicin.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
